Figure 3. Patients with LBCL who underwent SCT had significantly longer response duration than patients who received LR without SCT.

However, patients with MCL who underwent SCTdid not show any benefit in response duration. (a) Durations of response to lenalidomide + rituximab (LR) in MCL patients who underwent SCT and those who did not. (b)Durations of response to LR in LBCL patients who underwent SCT and those who did not.